Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

INKT vs FMKT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

INKT Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 5–3 Matrix Metrics)

INKT Overall Winner 6-Pillar Tally: INKT 3 – 0 FMKT (3 Tie) Matrix Metrics: INKT 5 – 3 FMKT

As of Nov 20, 2026, MiNK Therapeutics, Inc. (INKT) is the stronger overall head-to-head candidate over The Free Markets ETF (FMKT) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). INKT carries a Unified Composite Score of 42.8/100 (HOLD) at $8.02 (N/M Forward P/E, -5720.7% operating margin), whereas FMKT carries 44.7/100 (HOLD) at $19.88 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While FMKT currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. INKT 42.8/100 HOLD), INKT captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (-5720.7% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: INKT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile FMKT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About INKT vs FMKT
INKT NASDAQ Head-to-Head Winner
MiNK Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$8.02
-6.85% 1D
Market Cap $44.2M
TTM Revenue $200,000
Forward P/E N/M
Beta / 30D Vol 0.59β · 55% Vol
Unified Composite Score
42.8 / 100 HOLD
Tech 33.0 Fund 45.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.5%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $9.98 · SMA50: $10.80
FMKT NYSE Arca
The Free Markets ETF
Institutional Equity
$19.88
-1.4% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.91β · 16% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.1%), weak momentum, RSI 28
RSI-14: 28.1 · SMA20: $20.94 · SMA50: $21.46

6-Pillar Scorecard Institutional Category Breakdown (INKT 3 – 0 FMKT)

Columns: Metric · INKT · FMKT
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale INKT
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $200,000 N/A
Market Cap $44.2M N/A
3. Profitability & Quality INKT
Gross Margin 100.0% N/A
Operating Margin -5720.7% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -1239.0% N/A
4. Balance Sheet & Cash Flow INKT
Cash Generation (TTM) -$6.3M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage -1239.0% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: INKT (5) vs FMKT (3)
Institutional Metric INKT FMKT Criterion Row Edge
Market Capitalization
Scale
$44.2M N/A Larger Scale INKT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth INKT
Operating Margin (TTM)
Profitability
-5720.7% N/A Higher Margin INKT
Net Profit Margin
Profitability
0.0% N/A Higher Margin INKT
Return on Equity (ROE)
Capital Efficiency
-1239.0% N/A Higher ROE INKT
52-Week Range Position
Momentum
3% ($8–$17) 10% ($20–$23) Stronger Trend FMKT
Beta / 30D Volatility
Risk Regime
0.59β · 55% Vol 0.91β · 16% Vol Lower Realized Risk FMKT
Unified Institutional Score
Composite Signal
42.8 / 100 (HOLD) 44.7 / 100 (HOLD) Higher Composite FMKT
Trailing 12M Revenue (USD)
Operating Scale
$200,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.3M (-1239.0% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FMKT +13.36 pp
INKT: -20.28% · FMKT: -6.92%
3M Horizon FMKT +20.6 pp
INKT: -32.15% · FMKT: -11.55%
6M Horizon FMKT +14.91 pp
INKT: -26.22% · FMKT: -11.31%
1Y Horizon FMKT +17.78 pp
INKT: -27.22% · FMKT: -9.44%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on INKT vs FMKT. Trailing 12-month operating profitability (INKT -5720.7% vs FMKT N/A) and valuation multiples (INKT N/M vs FMKT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

INKT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$200,000
Gross Margin100.0%
Op. Margin-5720.7%
ROE / Fwd P/E-1239.0% · N/M
FMKT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
INKT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact INKT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FMKT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FMKT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
INKT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $44.2M market capitalization and -5720.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FMKT Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ INKT vs FMKT Key Questions & Quantitative Answers

As of Nov 20, 2026, MiNK Therapeutics, Inc. (INKT) is the stronger overall head-to-head candidate over The Free Markets ETF (FMKT) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). INKT carries a Unified Composite Score of 42.8/100 (HOLD) at $8.02 (N/M Forward P/E, -5720.7% operating margin), whereas FMKT carries 44.7/100 (HOLD) at $19.88 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While FMKT currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. INKT 42.8/100 HOLD), INKT captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (-5720.7% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: INKT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile FMKT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

INKT leads the Growth & Scale pillar: INKT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $200,000 TTM revenue (100.0% gross margin, -5720.7% operating margin), compared with FMKT at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, INKT generates $200,000 in USD-normalized revenue versus N/A for FMKT. In operating R&D and SG&A reinvestment, INKT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FMKT.

INKT and FMKT trade at balanced relative valuation multiples. INKT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas FMKT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INKT (-1239.0% ROE) versus FMKT (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, INKT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 55% Vol realized risk). By comparison, FMKT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.91β · 16% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.